DOCSLIB.ORG

2018 Abstract Book

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

CONTENTS Table of Contents INFORMATION Continuing Medical Education .................................................................................................5 Guidelines for Speakers ..........................................................................................................6 Guidelines for Poster Presentations .........................................................................................8 SPEAKER ABSTRACTS Abstracts ...............................................................................................................................9 POSTER ABSTRACTS Basic Research (Location – Room 101) ...............................................................................63 Clinical (Location – Room 8) ..............................................................................................141 2018 Joint Global Neurofibromatosis Conference · Paris, France · November 2-6, 2018 | 3 4 | 2018 Joint Global Neurofibromatosis Conference · Paris, France · November 2-6, 2018 EACCME European Accreditation Council for Continuing Medical Education 2018 Joint Global Neurofibromatosis Conference Paris, France, 02/11/2018–06/11/2018 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) for a maximum of 27 European CME credits (ECMEC®s). Each medical specialist should claim only those credits that he/she actually spent in the educational activity. The EACCME® is an institution of the European Union of Medical Specialists (UEMS), www.uems.net. Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credits to AMA credits can be found at www.ama-assn.org/education/earn-credit-participation-international-activities. Live educational activities occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC® credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada. 2018 Joint Global Neurofibromatosis Conference · Paris, France · November 2-6, 2018 | 5 IMPORTANT NOTES Guidelines for Speakers The Organizing Committee of the JOINT GLOBAL NEUROFIBROMATOSIS Conference will do its utmost to help authors for their presentations and to facilitate their arrival and stay at the conference. Please take a few minutes to read the following guidelines regarding the on-site organisation of the meeting for the smooth running of the sessions. A speakers’ preview room will be installed in room 103 on the 1st floor of the Maison de la Chimie, Paris (follow signs on site). Its role will be to manage the following: • Coordinate and ensure the overall smooth running of the conference sessions, • Follow the general schedule of the sessions, • Assist speakers for any requests they may have onsite. PLATFORM PRESENTATIONS In order to match with the most recent technology, the conference meeting room will be equipped with a video-projector and a laptop at the lectern. All speakers are requested to use the PREVIEW ROOM (follow signs on site), which can be accessed once you have picked up your badge at the Welcome desk. Each speaker should also check in the final Programme that the time of his/her session has not been modified. We kindly ask you to keep the time limit in mind and remember to save time for discussion! Qualified personnel will act as liaison between speakers and projectionists: speakers will not have access to the projection rooms; therefore speakers must go to the PREVIEW ROOM to hand in their computer assisted presentations that will be transferred to the conference room on time. Speakers are entirely responsible for the order, the loading and the pre-projection of their computer assisted presentation, using the equipment made available by the organisers. PRESENTATION (POWER-POINT STYLE) To avoid delays caused by switching on computers on the platform, booting up computers and potential compatibility problems, the Organising Committee has made available to speakers the standard A/V system used in the convention sector. There will be a master computer in the meeting room and to ensure smooth transition between speakers and appropriate technical support, the Organisers request that speakers do not connect their own laptop. Every speaker has to go to the Preview room beforehand to provide his/her PowerPoint presentation. OFFICIAL LANGUAGE The official language of the Conference is English, which means that all presentations and questions must be delivered in ENGLISH. FORMAT – PRESENTATION Only Presentations for PC’s (Windows latest versions) and PC’s compatible (to avoid problems of compatibility between PC’s and MAC, please use fonts Presentations must be displayed in 16:9. compatible with both PC’s and MAC) will be accepted, (no UNIX). Your presentation should be saved in the .pdf or .pptx format only. Other formats will not be accepted. • If you have pictures, they must be under the following format: .jpg, .png, or .gif, format (.pict prohibited). • If you have video files attached to your power point presentation, they must be in the following format: .mpg, .mpeg, .avi, .wmv, mp4 or .mov and must be saved in the same folder as the presentation. When saving your final presentation on a USB stick, make sure to include your video files and all links to these multimedia files. 6 | 2018 Joint Global Neurofibromatosis Conference · Paris, France · November 2-6, 2018 IMPORTANT NOTES Guidelines for Speakers DEPOSITING OF FILE • Your computer file must be handed over to the staff of the PREVIEW ROOM, either on a memory stick or a hard drive, as far in advance as possible and ONE AND A HALF hour BEFORE the beginning of each session AT THE LATEST. The presentation for an early morning session should be handed over the evening before. • In the PREVIEW ROOM, you will be assisted by a technician, who will help you to transfer your presentation to the internal network. You will also be able to review your presentation and to verify that it has been transferred correctly to the network. • The opening hours of the PREVIEW ROOM during the Conference will be: Friday, 2 November 2018 from 09:00 to 19:00 Saturday, 3 November 2018 from 07:30 to 18:30 Sunday, 4 November 2018 from 08:00 to 18:30 Monday, 5 November 2018 from 07:30 to 18:30 Tuesday, 6 November 2018 from 07:30 to 14:00 • All presentations will be considered as confidential by our staff and removed from the system at the end of the conference. IN THE MEETING ROOM • Your presentation will be sent directly to the meeting room through the internal computer network of the venue. The PC on the lectern is programmed in 16/9 and is linked to a video-projector. • Once the presentation is launched, you, the speaker, will control the program. By clicking on the mouse, your computer assisted slides will go on as usual. • Please, do NOT come at the last minute with your own laptop to the meeting room: you will NOT be able to connect it. Go to the PREVIEW ROOM in time beforehand. 2018 Joint Global Neurofibromatosis Conference · Paris, France · November 2-6, 2018 | 7 IMPORTANT NOTES Guidelines for Poster Presentations The Organizing Committee of the JOINT GLOBAL NEUROFIBROMATOSIS Conference will do its utmost to help authors for their presentations and to facilitate their arrival and stay at the conference. The Poster exhibition will be accessible from Friday to Monday in the exhibition area of the Maison de la Chimie, Paris. SET-UP/REMOVAL INSTRUCTIONS Mounting Friday, 2 November 2018 From 15:30 to 20:00 Removing Monday, 5 November 2018 From 16:45 to 18:45 POSTER SESSIONS The posters will be discussed in front of the poster boards during the dedicated sessions on Saturday and Sunday. In the dedicated session slot, the presenting author must be available next to his/her dedicated board to present and discuss the poster. BASIC RESEARCH POSTERS Saturday, 3 November 2018 From 18:00 to 19:30 Room 101 – level 1 CLINICAL RESEARCH POSTERS Sunday, 4 November 2018 From 17:25 to 18:55 Room 8 – ground floor POSTER DIMENSION AND FORMAT The poster must not exceed 120 cm in height and 90 cm in width, PORTRAIT ONLY. LANGUAGE Your poster must be written in ENGLISH. POSTER CONTENTS Each poster should contain, in addition to the scientific elements, the title of the selected abstract as submitted, and the full names and affiliation of contributing authors. Text, tables and drawings for figures should be large enough to be seen from a 2 meters distance. Illustrations should be used to convey important points; diagrams, graphs, bar charts, scatter grams, pie charts and photographs will enhance your presentation. Make short statements, avoid long explanatory sentences. MATERIALS Your poster should not exceed 120 cm high and 90 cm wide (Portrait only) in order to fit the poster board. Prepare your material beforehand so that it will fit neatly into the space available and can be easily attached to the board. Suitable fixing materials will be provided by the Conference organizers. There will be a poster helpdesk close to the poster area, where staff will be happy to assist you. Thin cardboard is more suitable than paper. Use a computer or enlarge a typed text by photographic methods. If you can have your poster produced by your institution, the final effect is more professional. 8 | 2018 Joint Global Neurofibromatosis Conference · Paris,
Recommended publications
  • Uniform Faint Reticulate Pigment Network - a Dermoscopic Hallmark of Nevus Depigmentosus

    Uniform Faint Reticulate Pigment Network - a Dermoscopic Hallmark of Nevus Depigmentosus

    Our Dermatology Online Letter to the Editor UUniformniform ffaintaint rreticulateeticulate ppigmentigment nnetworketwork - A ddermoscopicermoscopic hhallmarkallmark ooff nnevusevus ddepigmentosusepigmentosus Surit Malakar1, Samipa Samir Mukherjee2,3, Subrata Malakar3 11st Year Post graduate, Department of Dermatology, SUM Hospital Bhubaneshwar, India, 2Department of Dermatology, Cloud nine Hospital, Bangalore, India, 3Department of Dermatology, Rita Skin Foundation, Kolkata, India Corresponding author: Dr. Samipa Samir Mukherjee, E-mail: [email protected] Sir, ND is a form of cutaneous mosaicism with functionally defective melanocytes and abnormal melanosomes. Nevus depigmentosus (ND) is a localized Histopathologic examination shows normal to hypopigmentation which most of the time is congenital decreased number of melanocytes with S-100 stain and and not uncommonly a diagnostic challenge. ND lesions less reactivity with 3,4-dihydroxyphenylalanine reaction are sometimes difficult to differentiate from other and no melanin incontinence [2]. Electron microscopic hypopigmented lesions like vitiligo, ash leaf macules and findings show stubby dendrites of melanocytes nevus anemicus. Among these naevus depigmentosus containing autophagosomes with aggregates of poses maximum difficulty in differentiating from ash melanosomes. leaf macules because of clinical as well as histological similarities [1]. Although the evolution of newer diagnostic For ease of understanding the pigmentary network techniques like dermoscopy has obviated the
  • 14954 Spry2 (D3G1A) Rabbit Mab

    14954 Spry2 (D3G1A) Rabbit Mab

    Revision 1 C 0 2 - t Spry2 (D3G1A) Rabbit mAb a e r o t S Orders: 877-616-CELL (2355) [email protected] 4 Support: 877-678-TECH (8324) 5 9 Web: [email protected] 4 www.cellsignal.com 1 # 3 Trask Lane Danvers Massachusetts 01923 USA For Research Use Only. Not For Use In Diagnostic Procedures. Applications: Reactivity: Sensitivity: MW (kDa): Source/Isotype: UniProt ID: Entrez-Gene Id: WB, IP H M R Endogenous 35 Rabbit IgG O43597 10253 Product Usage Information 7. Sánchez, A. et al. (2008) Oncogene 27, 4969-72. 8. Frank, M.J. et al. (2009) Blood 113, 2478-87. Application Dilution 9. Yim, D.G. et al. (2015) Oncogene 34, 474-84. 10. Okur, M.N. et al. (2014) Mol Cell Biol 34, 271-9. Western Blotting 1:1000 11. Mason, J.M. et al. (2004) Mol Biol Cell 15, 2176-88. Immunoprecipitation 1:100 12. Edwin, F. et al. (2009) Mol Pharmacol 76, 679-91. 13. Fong, C.W. et al. (2003) J Biol Chem 278, 33456-64. Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody. Specificity / Sensitivity Spry2 (D3G1A) Rabbit mAb recognizes endogenous levels of total Spry2 protein. Species Reactivity: Human, Mouse, Rat Source / Purification Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro71 of human Spry2 protein. Background The Sprouty (Spry) family of proteins are antagonists of receptor tyrosine kinase (RTK)- induced signaling (1, 2).
  • Pityriasis Alba Revisited: Perspectives on an Enigmatic Disorder of Childhood

    Pityriasis Alba Revisited: Perspectives on an Enigmatic Disorder of Childhood

    Pediatric ddermatologyermatology Series Editor: Camila K. Janniger, MD Pityriasis Alba Revisited: Perspectives on an Enigmatic Disorder of Childhood Yuri T. Jadotte, MD; Camila K. Janniger, MD Pityriasis alba (PA) is a localized hypopigmented 80 years ago.2 Mainly seen in the pediatric popula- disorder of childhood with many existing clinical tion, it primarily affects the head and neck region, variants. It is more often detected in individuals with the face being the most commonly involved with a darker complexion but may occur in indi- site.1-3 Pityriasis alba is present in individuals with viduals of all skin types. Atopy, xerosis, and min- all skin types, though it is more noticeable in those with eral deficiencies are potential risk factors. Sun a darker complexion.1,3 This condition also is known exposure exacerbates the contrast between nor- as furfuraceous impetigo, erythema streptogenes, mal and lesional skin, making lesions more visible and pityriasis streptogenes.1 The term pityriasis alba and patients more likely to seek medical atten- remains accurate and appropriate given the etiologic tion. Poor cutaneous hydration appears to be a elusiveness of the disorder. common theme for most riskCUTIS factors and may help elucidate the pathogenesis of this disorder. The Epidemiology end result of this mechanism is inappropriate mel- Pityriasis alba primarily affects preadolescent children anosis manifesting as hypopigmentation. It must aged 3 to 16 years,4 with onset typically occurring be differentiated from other disorders of hypopig- between 6 and 12 years of age.5 Most patients are mentation, such as pityriasis versicolor alba, vitiligo, younger than 15 years,3 with up to 90% aged 6 to nevus depigmentosus, and nevus anemicus.
  • Revision of Diagnostic Criteria for Neurofibromatosis

    Revision of Diagnostic Criteria for Neurofibromatosis

    Revision of Diagnostic Criteria for Neurofibromatosis Gareth Evans, MD, St. Mary’s Hospital/University of Manchester, UK Susan Huson, MD, Consultant Geneticist, UK Eric Legius, MD, PhD, University of Leuven, Belgium Ludwine Messiaen, PhD, University of AlaBama, Birmingham, USA Scott Plotkin, MD, PhD, Massachusetts General Hospital, USA Pierre Wolkenstein, MD, PhD, Hôpital Henri-Mondor, France 2019 NF Conference San Francisco, CA September 21, 2019 Revision of the Diagnostic Criteria of the Neurofibromatoses 92 medical specialists 20 countries 5 continents We want your feedback! Send email to: [email protected] Participants in revision process: Leadership team Clinical Epidemiology Health Services Research: Ophthalmology: • Gareth Evans • Nilton Rezende • Vanessa Merker • Robert Avery • Sue Huson • Catherine Cassiman • Eric Legius Clinical Genetics: Internal Medicine: Pathology: • Ludwine Messiaen • Dorothy Halliday • Luiz Oswaldo Carneiro • Karin Cunha • Scott Plotkin • Maurizio Clementi Rodrigues • Anat Stemmer-Rachamimov • Pierre Wolkenstein • Arvid Heiberg • Patrice Pancza • Joanne Ngeow Scientists: Pediatrics: • Shay Ben-Schachar • Miriam Smith • Outside Experts: • Bruce Korf • Marco Giovannini Rianne Oostenbrink • • Monique Anten • Mimi Berman • Eduard Serra Robert Listernick • Jaan Toelen • Betty Schorry • Juha Peltonen Pediatric Hematology and • Arthur Aylsworth • Gareth Evans Oncology: • Meredith Wilson • Ignacio Blanco Molecular Genetics: • Michael Fisher • Helen Hanson • Dusica Babovic-Vuksanovic •Laura Papi • Christopher
  • Phacomatosis Spilorosea Versus Phacomatosis Melanorosea

    Phacomatosis Spilorosea Versus Phacomatosis Melanorosea

    Acta Dermatovenerologica 2021;30:27-30 Acta Dermatovenerol APA Alpina, Pannonica et Adriatica doi: 10.15570/actaapa.2021.6 Phacomatosis spilorosea versus phacomatosis melanorosea: a critical reappraisal of the worldwide literature with updated classification of phacomatosis pigmentovascularis Daniele Torchia1 ✉ 1Department of Dermatology, James Paget University Hospital, Gorleston-on-Sea, United Kingdom. Abstract Introduction: Phacomatosis pigmentovascularis is a term encompassing a group of disorders characterized by the coexistence of a segmental pigmented nevus of melanocytic origin and segmental capillary nevus. Over the past decades, confusion over the names and definitions of phacomatosis spilorosea, phacomatosis melanorosea, and their defining nevi, as well as of unclassifi- able phacomatosis pigmentovascularis cases, has led to several misplaced diagnoses in published cases. Methods: A systematic and critical review of the worldwide literature on phacomatosis spilorosea and phacomatosis melanorosea was carried out. Results: This study yielded 18 definite instances of phacomatosis spilorosea and 14 of phacomatosis melanorosea, with one and six previously unrecognized cases, respectively. Conclusions: Phacomatosis spilorosea predominantly involves the musculoskeletal system and can be complicated by neuro- logical manifestations. Phacomatosis melanorosea is sometimes associated with ancillary cutaneous lesions, displays a relevant association with vascular malformations of the brain, and in general appears to be a less severe syndrome.
  • Disclosure Summary for CME Learners ATS 2017 International Conference - Washington D.C

    Disclosure Summary for CME Learners ATS 2017 International Conference - Washington D.C

    American Thoracic Society - Disclosure Summary for CME Learners ATS 2017 International Conference - Washington D.C. - May 19-24, 2017 1) RELEVANT COMMERCIAL INTERESTS DISCLOSED BY CME PLANNERS AND PRESENTERS Initial Report as of May 15, 2017 Use Adobe PDF "Find" option to search for specific name. Presenter disclosures may continue on a successive page, or begin on a preceding page. Agrawal, Rishi Name of Commercial Interest and Type(s) of Relationship with that Commercial Interest Boehringer Ingelheim b.v. Speaker Agusti, Alvar Name of Commercial Interest and Type(s) of Relationship with that Commercial Interest Almirall Research Support Speaker Advisory Committee Name of Commercial Interest and Type(s) of Relationship with that Commercial Interest AstraZeneca Pharmaceuticals LP Speaker Advisory Committee Research Support Name of Commercial Interest and Type(s) of Relationship with that Commercial Interest Boehringer Ingelheim b.v. Advisory Committee Name of Commercial Interest and Type(s) of Relationship with that Commercial Interest GlaxoSmithKline, LLC. Advisory Committee Research Support Speaker Name of Commercial Interest and Type(s) of Relationship with that Commercial Interest Teva Pharmaceuticals USA, Inc. Speaker Advisory Committee Research Support Name of Commercial Interest and Type(s) of Relationship with that Commercial Interest Novartis Pharma AG Speaker Advisory Committee Name of Commercial Interest and Type(s) of Relationship with that Commercial Interest Merck Sharp & Dohme Corporation Advisory Committee Research Support Speaker 1 of 106 Agusti, Alvar Name of Commercial Interest and Type(s) of Relationship with that Commercial Interest Menarini Speaker Research Support Akulian, Jason A. Name of Commercial Interest and Type(s) of Relationship with that Commercial Interest Veran Medical Technologies, Inc.
  • Modulation of the Progenitor Cell and Homeostatic Capacities of Müller Glia Cells in Retina

    Modulation of the Progenitor Cell and Homeostatic Capacities of Müller Glia Cells in Retina

    Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1201 Modulation of the Progenitor Cell and Homeostatic Capacities of Müller Glia Cells in Retina Focus on α2-Adrenergic and Endothelin Receptor Signaling Systems MOHAMMAD HARUN-OR-RASHID ACTA UNIVERSITATIS UPSALIENSIS ISSN 1651-6206 ISBN 978-91-554-9527-5 UPPSALA urn:nbn:se:uu:diva-281569 2016 Dissertation presented at Uppsala University to be publicly examined in B21, BMC, Husagatan 03, Uppsala, Thursday, 19 May 2016 at 09:15 for the degree of Doctor of Philosophy (Faculty of Medicine). The examination will be conducted in English. Faculty examiner: Docent Per Ekström (Lund University). Abstract Harun-Or-Rashid, M. 2016. Modulation of the Progenitor Cell and Homeostatic Capacities of Müller Glia Cells in Retina. Focus on α2-Adrenergic and Endothelin Receptor Signaling Systems. Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1201. 73 pp. Uppsala: Acta Universitatis Upsaliensis. ISBN 978-91-554-9527-5. Müller cells are major glial cells in the retina and have a broad range of functions that are vital for the retinal neurons. During retinal injury gliotic response either leads to Müller cell dedifferentiation and formation of a retinal progenitor or to maintenance of mature Müller cell functions. The overall aim of this thesis was to investigate the intra- and extracellular signaling of Müller cells, to understand how Müller cells communicate during an injury and how their properties can be regulated after injury. Focus has been on the α2-adrenergic receptor (α2-ADR) and endothelin receptor (EDNR)-induced modulation of Müller cell-properties after injury.
  • Geslaagdenkrant 2016 2 HET BELANG VAN LIMBURG

    Geslaagdenkrant 2016 2 HET BELANG VAN LIMBURG

    wij zijn geslaagd! geslaagdenKRanT 2016 2 HET BELANG VAN LIMBURG aerts, Beringen. Handelswetenschappen en bedrijfskunde: Hogere ZeevaartscHool onderscheiding: ester swennen, genk. antwerpen Master in de Audiovisuele Kunsten Bachelor in het bedrijfsmanagement voldoende wijze: marieke stulens, Bilzen. onderscheiding: vladimir stonis, sint-truiden. Nautische Wetenschappen: onderscheiding: nele vandael, genk. voldoening: Hamza mouatassim, genk. Master in de Nautische Wetenschappen Onderwijs: onderscheiding: Jonathan vandenbossche, lommel. luca scHool oF arts Bachelor in het onderwijs: secundair onderwijs voldoening: marcella schetz, opitter. MA beeldende kunsten (Genk): erasmusHogescHool Sociaal-agogisch werk: Afstudeerrichting Fotografie Brussel met onderscheiding: Boumediene Belbachir, genk. Bachelor in de gezinswetenschappen op voldoende wijze: Jonas camps, Hechtel. onderscheiding: anne-martje Beckers, lummen; Kristel Management, Media & Maatschappij: cuyvers, Beringen; sara De Becker, Heers; nadine MA productdesign (Genk): Bachelor in het Communicatiemanagement Hermans, Dilsen-stokkem; an van lishout, Heusden- voldoende wijze: nele couwberghs, tessenderlo; Zolder; Dagmar vandebroek, Koersel. Afstudeerrichting Fotografie voldoening: marleen Bovie, tongeren; christine lavrey- maximiljaan van der Beken, Zonhoven. Katrijn caelen, genk. onderscheiding: mathijs vanduffel, overpelt. sen, Hasselt; valerie monnens, Heusden-Zolder; sandra Afstudeerrichting Communicatie- en Multime- vossen, Bocholt. Bachelor in het Hotelmanagement diadesign Bachelor
  • Juilliard Dance

    Juilliard Dance

    Juilliard Dance Senior Graduation Concert 2019 Welcome to Juilliard Dance Senior Graduation Concert 2019 Tonight, you will experience the culmination of a transformative four-year journey for the senior class of Juilliard Dance. Through rigorous physical training and artistic and intellectual exploration, all of the fourth-year dancers have expanded the possibilities of their movement abilities, stretching beyond what they thought possible when entering the program as freshmen. They have accepted the challenge of what it means to be a generous citizen artist and hold that responsibility close to their hearts. Chosen by the dancers, the solos and duets presented tonight have been commissioned for this evening or acquired from existing repertory and staged for this singular occasion. The works represent the manifestation of an evolution of growth and the discovery of their powerfully unique artistic voices. I am immensely proud of each and every fourth-year artist; it has been a joy and an honor to get to know the senior class, a group of individuals who will inevitably change the landscape of the field of dance as it exists today. Please join me for a standing ovation, cheering on the members of the class of 2019 as they take the stage for the last time together in the Peter Jay Sharp Theater. Well done, dancers—we thank you for your beautiful contributions to our Juilliard community and to the world beyond our campus. Sincerely, Little mortal jump Alicia Graf Mack Director, Juilliard Dance Cover: Alejandro Cerrudo's This page: Collaboration
  • Generation and Characterization of Spred-2 Knockout Mice

    Generation and Characterization of Spred-2 Knockout Mice

    Generation and Characterization of Spred-2 Knockout Mice Dissertation zur Erlangung des naturwissenschaftlichen Doktorgrades der Bayerischen Julius-Maximilians-Universität Würzburg vorgelegt von Dr. med. Karin Andrea Bundschu (geb. Geis) aus Frankfurt/Main Würzburg 2005 Eingereicht am: .....…………………………………………………………….. Mitglieder der Promotionskommission: Vorsitzender: ...……………………………………………………………….. Gutachter: Prof. Dr. U. Walter Gutachter: Prof. Dr. G. Krohne Betreuer: Dr. Kai Schuh Tag des Promotionskolloquiums: …………………………………………… Doktorurkunde ausgehändigt am: …………………………………………… The present study was performed under supervision of Dr. Kai Schuh in the group of Prof. Dr. med. Ulrich Walter in the Institute of Clinical Biochemistry and Pathobiochemistry at the Julius-Maximilians-University of Würzburg. The dissertation was part of the MD/PhD program, organized by the IZKF of the University of Würzburg. Declaration: Hereby, I declare that the submitted dissertation was completed by myself and no others and that I have not used any sources or materials other than those enclosed. Moreover, I declare that the following dissertation has not been submitted further in this form or any other form and has not been used for obtaining any other equivalent qualification in any other organization. Additionally, other than this degree I have not applied or will attempt to apply for any other degree or qualification in relation to this work. Würzburg, (Dr. med. Karin Andrea Bundschu) In love for my husband Christoph and our son Sebastian Table of Contents
  • Schwannomatosis: Tumors That Affect the Nervous System

    Schwannomatosis: Tumors That Affect the Nervous System

    In partnership with Primary Children’s Hospital Schwannomatosis: Tumors that affect the nervous system Schwannomatosis (sh-WAHN-no-muh-TOH-siss) is a genetic What are the signs disorder that causes noncancerous (benign) tumors, of schwannomatosis? called schwannomas, to grow on the peripheral and Signs of schwannomatosis include: spinal nerves. These tumors can cause pain that are • Chronic pain anywhere in the body hard to control. (caused by schwannomas pushing on the nerves) One in 40,000 people worldwide develop • Numbness or tingling schwannomatosis, a rare form of neurofibromatosis (new-roh-FIBE-row-muh-TOH-siss) each year. • Headaches Neurofibromatosis is a group of genetic disorders • Vision changes that affect the nervous system. • Weakness (including facial weakness) What causes schwannomatosis? • Problems with bowel movements Because schwannomatosis is a genetic disorder, your child either: • Trouble urinating • Inherited an abnormal gene from a parent, or Your child may have mild or severe pain, and they • Inherited a gene mutation may not have other symptoms of schwannomatosis until later. This makes it hard to diagnose Many children who have schwannomatosis are the the disorder. first in their family to have symptoms of the disorder. However, these children can then pass How is schwannomatosis diagnosed? schwannomatosis to their own children. Your child’s healthcare provider will look at your child and ask questions about their pain and symptoms. Sometimes the provider may be able to feel a tumor during a physical exam,
  • DGCR8 Microprocessor Defect Characterizes Familial Multinodular Goiter with Schwannomatosis

    DGCR8 Microprocessor Defect Characterizes Familial Multinodular Goiter with Schwannomatosis

    The Journal of Clinical Investigation CLINICAL MEDICINE DGCR8 microprocessor defect characterizes familial multinodular goiter with schwannomatosis Barbara Rivera,1,2,3 Javad Nadaf,2,3 Somayyeh Fahiminiya,4 Maria Apellaniz-Ruiz,2,3,4,5 Avi Saskin,5,6 Anne-Sophie Chong,2,3 Sahil Sharma,7 Rabea Wagener,8 Timothée Revil,5,9 Vincenzo Condello,10 Zineb Harra,2,3 Nancy Hamel,4 Nelly Sabbaghian,2,3 Karl Muchantef,11,12 Christian Thomas,13 Leanne de Kock,2,3,5 Marie-Noëlle Hébert-Blouin,14 Angelia V. Bassenden,15 Hannah Rabenstein,8 Ozgur Mete,16,17 Ralf Paschke,18,19,20,21,22 Marc P. Pusztaszeri,23 Werner Paulus,13 Albert Berghuis,15 Jiannis Ragoussis,4,9 Yuri E. Nikiforov,10 Reiner Siebert,8 Steffen Albrecht,24 Robert Turcotte,25,26 Martin Hasselblatt,13 Marc R. Fabian,1,2,3,7,15 and William D. Foulkes1,2,3,4,5,6 1Gerald Bronfman Department of Oncology, McGill University, Montreal, Quebec, Canada. 2Lady Davis Institute for Medical Research and 3Segal Cancer Centre, Jewish General Hospital, Montreal, Quebec, Canada. 4Cancer Research Program, McGill University Health Centre, Montreal, Quebec, Canada. 5Department of Human Genetics, McGill University, Montreal, Quebec, Canada. 6Division of Medical Genetics, Department of Medicine, McGill University Health Centre and Jewish General Hospital, Montreal, Quebec, Canada. 7Department of Experimental Medicine, McGill University, Montreal, Quebec, Canada. 8Institute of Human Genetics, University of Ulm and University of Ulm Medical Center, Ulm, Germany. 9Génome Québec Innovation Centre, McGill University, Montreal, Quebec, Canada. 10Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. 11Department of Diagnostic Radiology, McGill University, Montreal, Quebec, Canada.